Gland Pharma through its partner has launched Bortezomib for Injection, 3.5 mg/vial, single-dose vial in the US Market. It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial of Takeda Pharmaceuticals U.S.A.

Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.

Velcade has a market size of US $ 1,172 million for the twelve months ending March 2022, according to IQVIA.

Gland Pharma's partner has received the ANDA approval for the product from U.S. Food & Drug Administration (US FDA). Gland Pharma is manufacturing and supplying this product to its partner for the US market.